Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957858 | 1.00 | LRRK2 (0.43) | LRRK2NOS3NOS1CYP11B2CHRNB2 | |
| SCHEMBL15646504 | 0.84 | CHRNB2 (0.45) | CHRNB2CHRNA4KDM4E | |
| SCHEMBL2557306 | 0.83 | MAPK10 (0.45) | LRRK2RPS6KA3RPS6KA2RPS6KA1SMN1; SMN2 | |
| SCHEMBL12205229 | 0.82 | LRRK2 (0.51) | LRRK2NOS3NOS1CYP11B2CHRNB2 | |
| SCHEMBL2558075 | 0.80 | CHEK1 (0.43) | NOS3NOS1CYP11B2RPS6KA3RPS6KA2 | |
| SCHEMBL2558497 | 0.79 | RPS6KA3 (0.47) | LRRK2RPS6KA3LMNAMKNK1MKNK2 | |
| SCHEMBL1532956 | 0.77 | CHRNB2 (0.57) | LRRK2NOS3NOS1CYP11B2CHRNB2 | |
| SCHEMBL20896543 | 0.77 | KDM4E (0.40) | L3MBTL1RPS6KA3RPS6KA2RPS6KA1ALDH1A1 | |
| SCHEMBL31663316 | 0.75 | CYP11B2 (0.46) | CYP11B2PIK3CDMAPT | |
| SCHEMBL875323 | 0.75 | KMO (0.55) | ALDH1A1LMNAPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| EP-3887371-B1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | ESCAPE Bio, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| EP-3997081-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | Escape Bio, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20210309658-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2021007477-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2020240492-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | LRRK2 2602/4885NOS3 3268/4885NOS1 3486/4885 |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | LRRK2, PARK7, GDI2 | LRRK2 1/4885NOS3 2727/4885NOS1 3421/4885 |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | LRRK2 1/4885NOS3 2727/4885NOS1 3421/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | LRRK2 2602/4885NOS3 3268/4885NOS1 3486/4885 |
| US-20210309658-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | CFTR, QDPR, FPR1 | LRRK2 301/4885NOS3 2336/4885NOS1 1620/4885 |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | LRRK2 1/4885NOS3 3179/4885NOS1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.